{
  "nctId": "NCT04957082",
  "briefTitle": "Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake",
  "officialTitle": "Culturally-targeted Communication to Promote SARS-CoV-2 Antibody Testing in Saliva: Enabling Evaluation of Inflammatory Pathways in COVID-19 Racial Disparities",
  "protocolDocument": {
    "nctId": "NCT04957082",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2022-12-01",
    "uploadDate": "2024-05-29T15:55",
    "size": 757467,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04957082/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "SINGLE_GROUP",
  "masking": "SINGLE",
  "enrollmentInfo": {
    "enrollmentCount": 666,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-08-04",
    "completionDate": "2022-12-19",
    "primaryCompletionDate": "2022-12-19",
    "firstSubmitDate": "2021-07-06",
    "firstPostDate": "2021-07-12"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* African American or White, 18 or older, and enrolled in the Flint Registry\n\nExclusion Criteria:\n\n* All who do not meet inclusion criteria.",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number (Percentage) of Participants Requested to Participate in Saliva-based SARS-CoV-2 Antibody Testing",
        "description": "Number (Percentage) of participants who respond \"yes\" to be included in offer to participate in no cost SAR-CoV-2 salivary antibody test.",
        "timeFrame": "Immediately following didactic study portion and health communication randomization on day 1."
      },
      {
        "measure": "Number (Percentage) of Participants Who Requested Saliva-based SARS-CoV-2 Antibody Testing Participated in the Testing.",
        "description": "Number (Percentage) of participants that requested to participate in antibody testing who actually complete antibody testing.",
        "timeFrame": "8 weeks from the day of consenting to participate in the salivary-based SARS-CoV-2 antibody testing"
      },
      {
        "measure": "SARS-CoV-2 Antibody Testing Attitudes",
        "description": "Submeasure of Theory of Planned Behavior Indicating extent of a favorable attitude SARS-CoV-2 towards antibody testing (Seven point Likert Rating, with higher scores indicating more favorable Attitudes).",
        "timeFrame": "Immediately following didactic study portion and health communication randomization on day 1."
      },
      {
        "measure": "SARS-CoV-2 Antibody Testing Normative Beliefs",
        "description": "Sub-measure of Theory of Planned Behavior Indicating extent to which believes other people are favorable towards SARS-CoV-2 towards antibody testing (Seven point Likert Rating, with higher scores indicating stronger Normative Beliefs).",
        "timeFrame": "Immediately following didactic study portion and health communication randomization on day 1."
      },
      {
        "measure": "Antibody Testing Perceived Behavioral Control",
        "description": "Sub-measure of Theory of Planned Behavior Indicating Self Efficacy to Complete Antibody Testing (Seven point Likert Rating, with higher scores indicating greater Perceived Behavioral Control).",
        "timeFrame": "Immediately following didactic study portion and health communication randomization on day 1."
      },
      {
        "measure": "Antibody Testing Intentions",
        "description": "Sub-measure of Theory of Planned Behavior indicating Intentions to Complete Antibody Testing (Seven point Likert Rating, with higher scores indicating stronger screening Intentions).",
        "timeFrame": "Immediately following didactic study portion and health communication randomization on day 1."
      },
      {
        "measure": "Antibody Testing Anticipatory Racism",
        "description": "Extent to which participants believe that racism-related factors would diminish the value of SARS-CoV-2 antibody testing for self (Seven-point Likert rating, with higher scores indicating greater Anticipatory Racism).",
        "timeFrame": "Immediately following didactic study portion and health communication randomization on day 1."
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 7,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 7
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 99,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:39.098Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}